179 related articles for article (PubMed ID: 27234781)
1. Malignancy After Heart Transplantation Under Everolimus Versus Mycophenolate Mofetil Immunosuppression.
Wang YJ; Chi NH; Chou NK; Huang SC; Wang CH; Wu IH; Yu HY; Chen YS; Tsao CI; Shun CT; Tsai JT; Wang SS
Transplant Proc; 2016 Apr; 48(3):969-73. PubMed ID: 27234781
[TBL] [Abstract][Full Text] [Related]
2. Low Incidence of Malignancy After Heart Transplantation in Taiwan.
Wang YJ; Chi NH; Chou NK; Huang SC; Wang CH; Wu IH; Yu HY; Chen YS; Tsao CI; Shun CT; Tsai JT; Wang SS
Transplant Proc; 2016 Apr; 48(3):974-7. PubMed ID: 27234782
[TBL] [Abstract][Full Text] [Related]
3. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
[TBL] [Abstract][Full Text] [Related]
4. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
Rivinius R; Helmschrott M; Ruhparwar A; Schmack B; Klein B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Darche FF; Thomas D; Ehlermann P; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2015; 9():93-102. PubMed ID: 25552900
[TBL] [Abstract][Full Text] [Related]
5. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation.
Zuckermann A; Arizon JM; Dong G; Eisen HJ; Kobashigawa J; Lehmkuhl H; Ross H; Pelligrini C; Wang SS; Barten MJ
Transplantation; 2011 Sep; 92(5):594-600. PubMed ID: 21862955
[TBL] [Abstract][Full Text] [Related]
6. Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.
Watanabe T; Seguchi O; Nishimura K; Fujita T; Murata Y; Yanase M; Sato T; Sunami H; Nakajima S; Hisamatsu E; Sato T; Kuroda K; Hieda M; Wada K; Hata H; Ishibashi-Ueda H; Miyamoto Y; Fukushima N; Kobayashi J; Nakatani T
Int J Cardiol; 2016 Jan; 203():307-14. PubMed ID: 26523360
[TBL] [Abstract][Full Text] [Related]
7. Everolimus vs Mycophenolate Mofetil in Combination With Tacrolimus: A Propensity Score-matched Analysis in Liver Transplantation.
De Simone P; Carrai P; Coletti L; Ghinolfi D; Petruccelli S; Precisi A; Campani D; Marchetti P; Filipponi F
Transplant Proc; 2018 Dec; 50(10):3615-3620. PubMed ID: 30577246
[TBL] [Abstract][Full Text] [Related]
8. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine to mycophenolate mofetil transition and risk of squamous cell carcinoma after lung transplantation.
Vos M; Plasmeijer EI; van Bemmel BC; van der Bij W; Klaver NS; Erasmus ME; de Bock GH; Verschuuren EAM; Rácz E
J Heart Lung Transplant; 2018 Jul; 37(7):853-859. PubMed ID: 29680587
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients.
Billing H; Burmeister G; Plotnicki L; Ahlenstiel T; Fichtner A; Sander A; Höcker B; Tönshoff B; Pape L
Transpl Int; 2013 Sep; 26(9):903-9. PubMed ID: 23865768
[TBL] [Abstract][Full Text] [Related]
11. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
[TBL] [Abstract][Full Text] [Related]
12. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate.
Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
Transplant Proc; 2010 Apr; 42(3):938-9. PubMed ID: 20430209
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.
O'Neill JO; Edwards LB; Taylor DO
J Heart Lung Transplant; 2006 Oct; 25(10):1186-91. PubMed ID: 17045930
[TBL] [Abstract][Full Text] [Related]
14. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
Belliere J; Kamar N; Mengelle C; Allal A; Sallusto F; Doumerc N; Game X; Congy-Jolivet N; Esposito L; Debiol B; Rostaing L
Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
[TBL] [Abstract][Full Text] [Related]
16. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
17. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
Nelson LM; Andreassen AK; Andersson B; Gude E; Eiskjær H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
Transplantation; 2017 Nov; 101(11):2793-2800. PubMed ID: 28230646
[TBL] [Abstract][Full Text] [Related]
18. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
Ueno P; Felipe C; Ferreira A; Cristelli M; Viana L; Mansur J; Basso G; Hannun P; Aguiar W; Tedesco Silva H; Medina-Pestana J
Transplantation; 2017 Apr; 101(4):844-850. PubMed ID: 27490418
[TBL] [Abstract][Full Text] [Related]
19. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
[TBL] [Abstract][Full Text] [Related]
20. Renal Function Changes Under Everolimus Plus Cyclosporine or Everolimus Plus Tacrolimus After Heart Transplantation.
Chiang TY; Tsao CI; Wang SS
Transplant Proc; 2018 Nov; 50(9):2756-2758. PubMed ID: 30401391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
